ABVC BioPharma says 2023 financials error resolved in filed 10-K, no amendment needed

ABVC BIOPHARMA, INC.

Original 8-K on Apr 15, 2025 flagged 2023 financials for errors, requiring amendment.
After discussions with auditor Simon & Edward LLP, management determined corrections adequately addressed in the 2024 10-K filed Apr 15, 2025.
Company will not file the previously planned 2023 Amendment; prior non-reliance is effectively rescinded.
Auditor Simon & Edward LLP concurred with management's conclusion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.